LCP |
|
Vaxjo ID |
286 |
|
Vaccine Adjuvant Name |
LCP |
|
Adjuvant VO ID |
VO_0005774
|
|
Description |
A nanoparticle system co-delivering paclitaxel (chemotherapy) and miR-221/222 inhibitors (miRi) for synergistic anti-cancer effect. Combines a calcium phosphate core, lipid coating, and a PLGA-PEG polymer shell |
|
Stage of Development |
Research |
|
Components |
An artificial nanosized Ca2+ reservoir to promote DCs maturation |
|
Structure |
Core: CaP/miRi complex → coated with lipid (DOPA) → embedded in PLGA-b-PEG matrix with paclitaxel; ~30–80 nm particles |
|
Appearance |
Spherical nanoparticles observed via TEM; hollow CaP core with outer polymer/lipid shell |
|
Preparation |
<ul><li>CaP/miRi formed in water-in-oil emulsion</li><li>Lipid-coated with DOPA</li><li>Paclitaxel added in PLGA-b-PEG via nanoprecipitation</li></ul> |
|
Dosage |
In vitro: 20 pmol/mL miRi + 0.67 μg/mL paclitaxel; showed 80% cell death in TNBC cells |
|
Function |
Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors |
|
Safety |
Non-toxic polymer/lipid/CaP system; significantly reduced required paclitaxel dosage (~1%) for same effect |
| References |
Zhou et al., 2017: Zhou Z, Kennell C, Lee JY, Leung YK, Tarapore P. Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors. Nanomedicine : nanotechnology, biology, and medicine. 2017; 13(2); 403-410. [PubMed: 27520723].
|
